ERBB2 and breast carcinoma: miR-155 could not only predict the PR and the Her2 status but also its significant upregulation in postmenopausal samples and in patients of age greater than 40 years old made it a considerable breast cancer biomarker for postmenopausal patients or for those greater than 40 years old.